Discover how modern immunotherapy awakens T cells to shrink melanoma tumors, tracked by PET scans and used after surgery to prevent relapse. In this segment, Dr. Morrison provides clinical context ...

Learn how subcutaneous nivolumab shifts immunotherapy from IV infusions to quick thigh or abdominal injections, approved in late 2024.

Revolution Medicines’ pan-RAS inhibitor helped patients with a highly aggressive form of pancreatic cancer live an average of six months longer than chemotherapy, hitting a goal of the phase 3 study.

Pharmac is widening access to two melanoma medicines, giving cancer patients more funded immunotherapy options.

Anne Jordan was diagnosed with blood cancer in 2016. After multiple treatments of chemotherapy and radiation, her doctors recommended she consult Dr. Nakhle Saba, director of the CAR-T program at ...

I f your doctor has recommended chimeric antigen receptor (CAR) T-cell immunotherapy for large B-cell lymphoma (LBCL), you’ve likely already tried several standard treatments, and the cancer did not ...

TriSalus Life Sciences, Inc. (Nasdaq: TLSI) (the “Company”), an oncology company integrating novel delivery technology with standard of care therapies, and its investigational immunotherapeutic to ...

Fred Hutch Obliteride, Fred Hutch Cancer Center’s annual bike ride and 5K walk/run to support cancer research and care, is now open for registration.

Booking Health, a global medical travel provider, announced today the release of its 2026 report on advanced head and neck cancer treatment for international patients, outlining key developments in ...

Autolus Therapeutics (NASDAQ:AUTL) hosted an investor event focused on its acute lymphoblastic leukemia (ALL) program, ...

Confirmatory ZUMA-2 trial data led to full FDA approval of brexucabtagene autoleucel for patients with relapsed or refractory mantle cell lymphoma.

As cancer rates surge in Karnataka, the shift to daycare chemotherapy centers is transforming treatment accessibility, ...